Results 121 to 130 of about 744,004 (263)

Research on High Power Density Integrated Controller for EV

open access: yesKongzhi Yu Xinxi Jishu, 2011
For any electric vehicle (EV), whether pure, hybrid or fuel cell, the requirements for its electric drive system can be summarized as high power density, high power efficiency, high reliability and low cost etc.
LIU Jun, HU Wei, WEN Xuhui
doaj  

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak   +4 more
wiley   +1 more source

Proton-shuttling nanosheet membranes enable high-power-density protonic fuel cells. [PDF]

open access: yesSci Adv
He K   +14 more
europepmc   +1 more source

Acute Kidney Injury After Mechanical Thrombectomy for Stroke in Patients With Pre‐Existing Renal Impairment

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Acute kidney injury (AKI) is a common but often underrecognized complication in ischemic stroke patients undergoing mechanical thrombectomy, particularly among those with pre‐existing renal impairment. This study evaluated the incidence, risk factors, and clinical impact of AKI in this high‐risk population.
Michał Borończyk   +10 more
wiley   +1 more source

Near-field thermophotovoltaics for efficient heat to electricity conversion at high power density. [PDF]

open access: yesNat Commun, 2021
Mittapally R   +8 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy